EUCTR2004-002434-19-IT
Active, not recruiting
Not Applicable
A 6-week multicenter, randomized, double-blind, placebo-controlled, parallel group effficacy trial of 2 different dose regimens of lumiracoxib (100 mg bid and 200 mg od)in patients with primary knee osteoarthritis using naproxen 500 mg bid as a positive control
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- OVARTIS FARMA
- Enrollment
- 916
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A 6-week, multicenter, randomized, double-blind, parallel-group study to evaluate the combination of valsartan/HCTZ (160/12.5 mg with forced titration to a maximum dose of 320/25 mg) compared to valsartan monotherapy (160 mg with forced titration to 320 mg) as initial therapy in patients with severe hypertensioSevere hypertension (MSDBP = 110 mmHg and < 120 mmHg).EUCTR2005-003376-37-SIovartis Pharma Services AG528
Active, not recruiting
Not Applicable
A 6-week, multicenter, randomized, double-blind, parallel-group study to evaluate the combination of valsartan/HCTZ (160/12.5 mg with forced titration to a maximum dose of 320/25 mg) compared to valsartan monotherapy (160 mg with forced titration to 320 mg) as initial therapy in patients with severe hypertensioEUCTR2005-003376-37-ESovartis Pharma Services AG528
Active, not recruiting
Phase 1
A study to learn how well finerenone works; how safe it is; how it moves into, through, and out of the body; and the effects it has on the body when taken by children with chronic kidney disease and proteinuria in addition to angiotensin-converting enzyme inhibitor or angiotensin receptor blockerChronic kidney diseaseProteinuriaMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.1Level: PTClassification code 10037032Term: ProteinuriaSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2021-002071-19-NLBayer AG219
Active, not recruiting
Phase 1
A study to learn how well finerenone works; how safe it is; how it moves into, through, and out of the body; and the effects it has on the body when taken by children with chronic kidney disease and proteinuria in addition to angiotensin-converting enzyme inhibitor or angiotensin receptor blockerEUCTR2021-002071-19-ITBAYER AG219
Active, not recruiting
Phase 1
A study to learn how well finerenone works; how safe it is; how it moves into, through, and out of the body; and the effects it has on the body when taken by children with chronic kidney disease and proteinuria in addition to angiotensin-converting enzyme inhibitor or angiotensin receptor blockerChronic kidney diseaseProteinuriaMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.1Level: PTClassification code 10037032Term: ProteinuriaSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2021-002071-19-GRBayer AG219